3/13/2025

Janusmed kön och genus

Janusmed kön och genus – Jakavi

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C! C!
C! C!

Ruxolitinib – systemiskt

Ruxolitinib – systemiskt

Klass : C!

Visa all info

Skriv ut

Kontakta oss

  1. What is the Life Expectancy for Someone with Myelofibrosis?. Health Tree Foundation [www]. [cited 2024-11-14].

  2. Penna D, Lasho TL, Finke CM, Vallapureddy RR, Hanson CA, Ketterling RP et al. 20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. Am J Hematol. 2019;94(3):286-290.

  3. Verstovsek S, Yeleswaram S, Hou K, Chen X, Erickson-Viitanen S. Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis. Hematol Oncol. 2018;36(4):701-708.

  4. Gong X, Chen X, Kuligowski ME, Liu X, Liu X, Cimino E et al. Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies. Am J Clin Dermatol. 2021;22(4):555-566.

  5. Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A et al. Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer J. 2018;8(10):89.

  6. Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100(9):1139-45.

  7. Lee BH, Moon H, Chae JE, Kang KW, Kim BS, Lee J et al. Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea. J Clin Med. 2021;10(20):.

  8. Jakavi (ruxolitinib). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2024-03-21, cited 2024-11-14]

  9. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]

  1. What is the Life Expectancy for Someone with Myelofibrosis?. Health Tree Foundation [www]. [cited 2024-11-14].
  2. Penna D, Lasho TL, Finke CM, Vallapureddy RR, Hanson CA, Ketterling RP et al. 20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. Am J Hematol. 2019;94(3):286-290.
  3. Verstovsek S, Yeleswaram S, Hou K, Chen X, Erickson-Viitanen S. Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis. Hematol Oncol. 2018;36(4):701-708.
  4. Gong X, Chen X, Kuligowski ME, Liu X, Liu X, Cimino E et al. Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies. Am J Clin Dermatol. 2021;22(4):555-566.
  5. Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A et al. Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer J. 2018;8(10):89.
  6. Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100(9):1139-45.
  7. Lee BH, Moon H, Chae JE, Kang KW, Kim BS, Lee J et al. Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea. J Clin Med. 2021;10(20):.
  8. Jakavi (ruxolitinib). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2024-03-21, cited 2024-11-14]
  9. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]